Purpose: To evaluate the efficacy and tolerability of Levetiracetam (LEV) in the treatment of childhood epilepsy. Methods: Retrospective study, evaluated 38 patient in 6 months from Apr. 2008 to Dec. 2010 and treated with LEV. Results: There are 10 (26.3 percent) children under 1 year (1 in 2 months)
17 (44.7 percent) from 13 months to 6 years
11 (29 percent) over 6 years. Sex: Female/Male 16/22 (1/1.4). lime suffer from Epilepsy from 6 days to 9 years. Aetiology: idiopathic, crytogenic 21 percent, symptomatic 79 percent. The following seizure types and frequendes were notice: simple partial 21 percent, oomplex partial 10.6 percent, generalized tonic-donic seizures 50.1 percent, myoclonic 7.9 percent, West syndrome 5.2 percent, absence 5.2 percent. Test Haematology, AST, ALP, calcium total, calcium ionised, phosphorus inorganic, sodium, potasium, chloride, before and after 12 weeks and MRI. Time suffer frome epilepsy from 6 days to 9 years. Seizues frequency of patient (before treatement) from 2 to 20 in a month. Patients became seizures free in 8/38 (21.2 percent), redution of more than 50 percent seizures frequency in 57.8 percent patients, reduction less than 50 percent seizures frequency in 15.7 percent patients. The average dose used was 23.6 mg/kg (20-50mg/kg).Adverse effects was not seen. Livetiracetam effectived therapy in patient with partial onset and primary generalized tonic-clonic seizures.